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Affinity chromatography provides an excellent platform for protein purification, which
is a key step in the large scale downstream processing of therapeutic monoclonal
antibodies (Mabs). Protein A chromatography constitutes the gold standard for Mab
purification. However, the required acidic conditions (2.8–3.5) for elution from the affinity
matrix limit their applicability, particularly for next generation antibodies and antibody
fusion proteins, since denaturation and irreversible aggregation can occur due to the
acidic buffer conditions. Here we describe a generic procedure for the generation
of antigen-specific chromatography ligands with tailor-made elution conditions. To
this end, we generated a scFv-library based on mRNA from a chicken immunized
with human Fc. The antibody repertoire was displayed on yeast Saccharomyces
cerevisiae screened via FACS toward pH- and magnesium-responsive scFvs which
specifically recognize human IgG antibodies. Isolated scFvs were reformatted, produced
in Escherichia coli and immobilized on NHS-agarose columns. Several scFvs were
identified that mediated antibody binding at neutral pH and antibody recovery at pH
values of 4.5 and higher or even at neutral pH upon MgCl2 exposure. The iterative
screening methodology established here is generally amenable to the straightforward
isolation of stimulus-responsive antibodies that may become valuable tools for a variety
of applications.
Keywords: affinity chromatography, yeast display, protein purification, immune library, chicken antibody, single
chain fragment variable, downstream processing, protein A
INTRODUCTION
In the time period of 2014 to 2018 a total of 129 unique biopharmaceuticals were approved for
either the US or EU market raising the total number of approved biopharmaceuticals to 316.
The category of biopharmaceuticals contains monoclonal antibodies (mAbs), hormones, clotting
factors, enzymes and others. This heterogeneous group of molecules is mainly utilized in cancer,
inflammation-related, hemophilia and diabetes indications and is responsible for $188 bn sales
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in 2017 with expectations to reach nearly $400 bn in 2025 (Grand
View Research, 2017). With up to 65.5% of total sales, monoclonal
antibodies remain the most interesting protein scaffold. In the
recent decade, the market became more congested and multiple
molecules are utilized for similar indications. This leads to
an increase in competitive pressure, a motivation for research
and development of new low-cost production and purification
strategies (Walsh, 2018).
In the production process of proteins, downstream processing
is one of the major cost driving factors, accountable for 45–
90% of the whole manufacturing process costs, making it a
promising target for optimization (Straathof, 2011). Affinity
chromatography is a powerful tool for efficient purification
of the protein of interest (POI) omitting the need for
multiple chromatography steps (Harakas, 1994; MacLennan,
1995; Saraswat et al., 2013; Urh et al., 2009). However, the
genetic fusion of affinity tags to the POI is a putative origin
for immune reactions which should be avoided (Dingman and
Balu-Iyer, 2019). In the case of antibodies, natural occurring
affinity ligands exist, omitting the need for affinity tags. These
bacterial proteins can be found in Staphylococcus species (Protein
A, Protein G) or Peptostreptococcus species (Protein L) and mask
the bacteria from the immune system of the host organism
and are also known as virulence factors (Ricci et al., 2001;
Palmqvist et al., 2002). This strong natural interaction can be
exploited for affinity chromatography, where antibodies can be
efficiently bound onto a Protein A-agarose column (Duhamel
et al., 1979). This natural affinity comes with a drawback. For
the interruption of this tight interaction, harsh elution conditions
have to be applied. Commonly used Protein A chromatography
relies on glycine/citrate buffer compositions with a pH of 2.8–
3.5 to achieve high recovery. These acidic conditions are not well
tolerated by some antibodies and may lead to protein loss by
aggregation (Vázquez-Rey and Lang, 2011; Mazzer et al., 2015; Jin
et al., 2019) as well as structural changes such as deamidation and
backbone cleavage upon succinimide formation (Linhult et al.,
2005; Lu et al., 2019) and therefore result in less economical
production conditions. Intensive efforts have been made to
improve Protein A/G to overcome this intrinsic drawback. On
one hand, the high costs of Protein A/G columns have been
countered by improvements toward alkaline stability, allowing
more purifications cycles per column (Nilsson et al., 1987; Gulich
et al., 2002; Hahn et al., 2006). On the other hand, efforts have
been made to establish less acidic elution conditions by Protein
A/G engineering and rational design culminating in variants
that can be used with elution at pH 4.5 (Gulich et al., 2000;
Watanabe et al., 2009, 2019; Pabst et al., 2014; Tsukamoto et al.,
2014). Alternative approaches focus on temperature-dependent
elution (Koguma et al., 2013) or antibody binding upon calcium
supplementation and subsequent elution with EDTA at neutral
pH (Kanje et al., 2018; Scheffel et al., 2019).
Several alternative binding proteins have been developed
for Fc affinity purification purposes. For example, single-
domain antibody domains (VHH) have been isolated from
immunized camelids. For their use in downstream processing
applications gentle elution conditions should prevail and
these antibodies were therefore engineered toward pH- and
magnesium-responsive binding behavior (Klooster et al., 2007;
Detmers et al., 2010; Hermans et al., 2014). Further developments
focus on semi-synthetic protein scaffold libraries based on
i.e., a DNA-binding protein derived from a hyperthermophilic
crenarchaea called Sso7D (“Affitins”) (Gera et al., 2012; Behar
et al., 2016), “Affimers” based on cystatin and human stefin A
(McPherson and Tomlinson, 2014; Tiede et al., 2017), modular
leucine-rich repeat units called “Repebodies” (Heu et al., 2014),
and many more as elegantly reviewed by Škrlec et al. (2015)
not only limited to affinity chromatography but also for imaging
purposes and therapeutic applications (Bedford et al., 2017;
Simeon and Chen, 2018).
The goal of this study was to establish a generic screening
procedure for pH- and/or magnesium-responsive binders against
a given target via yeast surface display of a single chain fragment
variable (scFv) library obtained from immunized chickens for
use in affinity chromatography applications. Here we describe
a screening strategy that allows for isolation of high affinity
target binding antibodies that release their target at slightly
acidic pH or in combination with pH drop and elevated
magnesium concentrations. We used chickens for immunization
since the phylogenetic distance between avians and humans
is significantly increased, enhancing the probability to obtain
antibodies against human antigens bypassing antigen self-
tolerance related problems (Davies et al., 1995). Also, chicken
antibodies tend to be structural more rigid caused by non-
canonical disulfide bridges located in the CDRs and elevated body
temperature of avians (Prinzinger et al., 1991; Wu et al., 2012).
Additionally, the special genetic arrangement of the VH and VL
gene of chickens allows the amplification of the whole antibody
repertoire with two separate one-step PCRs using defined primer
pairs (Reynaud et al., 1985, 1987, 1989, 1991; Thompson and
Neiman, 1987; McCormack et al., 1993).
Here we show that the combination of avian immunization,
yeast surface display (YSD) and ultra-high throughput screening
by FACS results in the isolation of numerous human Fc-specific
pH- and magnesium-responsive scFvs. After immobilization they
displayed favorable binding and elution profiles and allowed for
target antibody purification using mild elution conditions.
MATERIALS AND METHODS
Immunization
The immunization of a pathogen-free adult laying hen (Gallus
gallus domesticus) was performed at Davids Biotechnologie
GmbH, Germany. The specimen was intramuscularly injected
with 150 µg SEED-Fc-protein (gift from Dr. S. Zielonka, Merck
KGaA, Darmstadt) (Davis et al., 2010; Muda et al., 2011)
in combination with immune adjuvant AddaVax (InvivoGen).
Boosters were given 2, 4, 5, and 8 weeks after the initial injection.
Immune response against the Fc-protein was determined after
5 weeks by antigen-specific titer determination using ELISA. The
chicken was sacrificed after 9 weeks and the total splenic RNA
was subsequently isolated using TriFast reagent (VWR).
Experimental procedures and animal care were in accordance
with EU animal welfare protection laws and regulations.
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Yeast Strains and Media
Saccharomyces cerevisiae EBY100 [MATa URA3-52 trp1 leu211
his31200 pep4::HIS3 prb111.6R can1 GAL (pIU211:URA3)]
(Thermo Fisher Scientific) cells were utilized for yeast surface
display. Prior to library generation, yeast cells were cultivated
in YPD medium composed of 20 g/L peptone/casein, 20 g/L
glucose and 10 g/L yeast extract supplemented with appropriate
antibiotics (ampicillin 100 mg/L, kanamycin sulfate 75 mg/L or
chloramphenicol 25 mg/L). The SD-CAA media for yeast cell
cultivation after library generation comprised 5.4 g/L Na2HPO4
and 8.6 g/L NaH2PO4 × H2O, 20 g/L glucose, 5 g/L ammonium
sulfate, 1.7 g/L yeast nitrogen base (without amino acids), and
5 g/L bacto casamino acids. For surface presentation induction,
SG-CAA medium was used which resembles SD-CAA but instead
of glucose, galactose was supplemented.
Library Construction
The generation of the scFv gene library was performed
as described by Grzeschik et al. (2019). Briefly, the VH
and VL genes were amplified with VH_gr_up/VH_SOE_lo
and VL_SOE_up/VL_gr_lo, respectively (Supplementary Table
S3), after cDNA synthesis and subsequent mRNA digestion.
Both fragments were fused in two additional PCR reactions
introducing a (Gly4Ser)3 linker sequence, amplifying the scFv
gene while adding overhangs at the 5′ and 3′ end of the scFv
gene for homologous recombination in yeast. The PCR amplicon
was subsequently purified. The pCT plasmid (Boder and Wittrup,
1997) which was used for surface presentation was digested
with NheI and BamHI (New England Biolabs) and purified
prior to gap repair cloning. The library generation with scFv
insert, pCT backbone and EBY100 yeast cells were performed
according to Benatuil et al. (2010).
Twelve transformation reactions were performed each
consisting of 4 µg digested pCT plasmid and 12 µg scFv insert.
The number of individual transformants was determined by
dilution plating after 3 days of cultivation at 30◦C.
Library Sorting
Prior to yeast cell sorting, the yeast library was cultivated
overnight in SD-CAA medium at 30◦C and 180 rpm.
Subsequently, the cell suspension was centrifuged at 4000
rcf and the medium aspirated. The cell pellet was utilized to
inoculate SG-CAA medium to a final cell density of 1 × 107
cells/mL followed by an incubation period of at least 12 h at
30◦C. Cells were harvested by centrifugation and washed once
in 1 mL PBS-B pH 7.4 [PBS + 0.1% (w/v) BSA] prior to the
staining procedure.
The presentation of the scFv molecules on the yeast cell
surface was verified either with an anti-c-myc antibody
(produced in house) and anti-mouse IgG FITC (Sigma Aldrich)
or anti-mouse IgG R-phycoerythrin (PE) (Sigma Aldrich)
as secondary labeling agent or anti-c-myc biotin antibody
(Miltenyi biotech) and Streptavidin-PE (Fisher Scientific)
or Streptavidin-allophycocyanin (APC) (Fisher Scientific),
respectively. The detailed staining strategy including working
dilution is summarized in Supplementary Table S1. The staining
steps are summarized in Supplementary Table S2.
In the screening process, daratumumab (Janssen-Cilag),
pertuzumab (Genentech) and cetuximab (Merck) were utilized.
Antibody binding was detected with anti-Human IgG (Fab
specific) -FITC (Sigma-Aldrich), Goat F(ab’)2 anti-Human
Kappa-PE (Southern Biotech) or Goat anti-Human IgG Fc
Secondary Antibody PE (Invitrogen) (Figure 1C). In the first
and second screening round SEED Fc protein (Merck KGaA) was
utilized conjugated with DyLight650 (Thermo Fisher Scientific).
Conjugation was performed according to the manufacturer’s
manual with 5-fold molar excess of NHS-DyLight650.
Yeast cells that were collected during the sorting process were
transferred into SD-CAA medium and cultivated for 48 h at
30◦C and 180 rpm before re-activating surface presentation by
inoculating SG-CAA medium for subsequent sorting. In each
sorting round, the total number of screened cells exceeded 10-
fold the number of cells in the previous sorting process to ensure
proper library coverage during sorting.
Bacterial Strains and Media
Escherichia coli Top10 cells [F− mcrA 1(mrr-hsdRMS-mcrBC)
ϕ80lacZ1M15 1lacX74 recA1 araD139 1(ara-leu) 7697 galU
galK rpsL (StrR) endA1 nupG λ-] (Thermo Fisher Scientific)
were used for transformation of golden gate assembly batches.
Cell cultivation was performed in dYT medium (yeast extract
10 g/L; peptone ex casein 16 g/L; NaCl 5 g/L). Correctly
assembled plasmids were rescued and subsequently transformed
into the SHuffle T7 Express strain (fhuA2 lacZ::T7 gene1 [lon]
ompT ahpC Etc gal λatt::pNEB3-r1-cDsbC (SpecR, lacIq) 1trxB
sulA11 R(mcr-73::miniTn10–TetS) [dcm] R(zgb-210::Tn10 –TetS)
endA1 1gor 1(mcrC-mrr)114::IS10) (New England Biolabs) for
expression. SHuffle T7 Express cells were cotransformed with
the pLysS Erv1p/DsbC plasmid (Veggiani and de Marco, 2011)
and transformants were maintained upon addition of 60 µg/ml
kanamycin and 25 µg chloramphenicol. Expression in SHuffle
T7 Express was conducted in SB medium (yeast extract 20 g/L;
peptone ex casein 32 g/L; NaCl 5 g/L; NaOH 1 N 5 mL).
Cloning, Expression, Purification of
Solitaire scFvs
Single clones with pH-responsive or magnesium-responsive
properties were reformatted into a pET30a expression plasmid
comprising BsaI-HF R©v2 sites for golden gate cloning (GGC). To
this end, scFv genes were amplified from the respective pCT
plasmid using scFv_chick_his_GG_up and scFv_chick_SII_GG_lo
primers (Supplementary Table S3) introducing BsaI restriction
sites for golden gate assembly as well as a 5′ His6-tag and 3′
StrepTagII (Johar and Talbert, 2017) for purification. The golden
gate assembly was performed with 75 ng pET30a backbone and
25 ng of the purified PCR amplicon. Plasmids with the correct
sequence were subsequently transformed into SHuffle T7 Express
E. coli cells containing a pLysS Erv1p/DsbC plasmid.
The expression of the scFvs was performed according to
Veggiani and de Marco (2011) in SB medium with a final
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FIGURE 1 | Summary of the sorting steps for the isolation of pH- and magnesium-responsive chicken-scFvs. In general, FACS plots show Fc-binding plotted on the
x-axis and surface presentation on the y-axis. Each plot contains 50,000 events. Detailed staining strategy is summarized in Supplementary Table S1.
(A) Enrichment of Fc-specific scFvs via YSD and FACS during the 1st and 2nd sorting rounds. (B) Summarized screening campaign for the isolation of
magnesium-responsive scFvs. The 3rd and 4th sorting rounds were performed to deplete scFv variants that bound regardless of the MgCl2 concentration by sorting
non-binding yeast cells after incubating the cells with 2 M MgCl2. The 5th sorting round was conducted in order to enrich IgG binding cells and to isolate single
clones. (C) Schematic depiction of yeast surface display. The scFv molecule (pdb: 4p48) is displayed on the yeast cell via aga2p-fusion. Surface presentation is
verified by staining the C-terminal c-Myc-tag. The scFv backbone is shown in blue, the CDRs are highlighted in orange. Antibody binding (pdb: 1igt) is verified
indirectly by fluorophore staining. The heavy chains are depicted in light blue, the light chains in green. (D) Consecutive sorting rounds to enrich pH-responsive
scFvs. The 3rd sorting round was conducted with an additional incubation step at pH 5.0 and non-binding yeast cells were isolated. The 4th sorting round was
performed in order to isolate yeast single clones. (E) General procedure for the analysis of single clones. Exemplarily, H9 and M9 analysis is depicted in a histogram,
respectively. Fc-binding is depicted on the x-axis and cell count on the y-axis. For H9, cells washed at pH 7.4 after target protein incubation are shown in orange,
cells washed at pH 6.0 in blue and cells washed at pH 5.0 are shown in red. M9-bearing cells are shown in the red histogram with non-Magnesium exposed cells
are shown in orange and cells exposed to 2 M MgCl2 are shown in red.
concentration of 0.1% arabinose and 1 mM IPTG at 18◦C,
180 rpm for at least 16 h.
Cells were harvested by centrifugation, lysed by sonication
and the soluble fraction was applied onto a HisTrap HP 5 mL
column (GE Healthcare) for purification. Chromatography was
performed on an ÄKTA Start FPLC system. As binding buffer
IMAC Buffer A (Tris/HCl 50 mM pH 7.5, NaCl 150 mM) was
utilized. Bound protein was eluted with IMAC Buffer B (Tris/HCl
50 mM pH 7.5, NaCl 150 mM, 1 M imidazole) in a linear gradient.
After the IMAC, the protein containing fractions were pooled
and diluted 1:2 with Buffer W (Iba Lifescience). As a second
purification step, the protein containing solution was applied
on a StrepTactin XT high capacity column (Iba Lifescience).
Column wash was performed with Buffer W and bound protein
was eluted with Buffer E (Iba Lifescience). Buffer exchange was
performed with a dialysis hose with a MWCO of 3 kDa with at
least 2 dialysis steps.
Protein Immobilization
Purified scFv protein was coupled to prepacked NHS-agarose
columns (GE Healthcare, 1 ml column volume) according to
the manufacturers protocol. To this end, 5 mg protein (in PBS
buffer) were slowly applied to the column with a contact time
of approx. 500 µl/15 min after rinsing the column with 6 ml
ice-cold HCl (1 mM) via a syringe. The column was cleared
from non-immobilized protein by washing the column with 2 ml
PBS. Subsequently, the column was washed with 6 ml Buffer Q
(500 mM Tris-HCl, 500 mM NaCl, pH 8.3), 6 ml Buffer QB
(100 mM sodium acetate, 500 mM NaCl, pH 4.0) and 6 ml
Buffer Q. After an incubation time of 60–90 min in Buffer Q
to quench unreacted NHS-groups, the column was subsequently
washed with 6 ml Buffer QB, 6 ml Buffer Q and 6 ml Buffer
QB, respectively. In the last step, the column was purged with
coupling buffer (PBS) and stored at 4◦C until further utilization.
The coupling efficiency was determined utilizing the Pierce
660 nm Protein Assay Reagent. Briefly, the flowthrough of the
coupling solution as well as the 3 ml coupling buffer wash
solution were collected after passing through the column. Fifty
µL of the solution was mixed with 750 µL assay solution. After
5 min incubation at RT, the absorbance at 660 nm was measured.
For each protein, a unique calibration curve was recorded
which was utilized to calculate the protein concentration in
the flowthrough.
Nano Differential Scanning Fluorimetry
Measurement
Melting point measurements were performed on a Prometheus
NT.48 instrument (NanoTemper Technologies). Ten µl of a
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1 mg/ml protein solution in PBS was filled into the capillaries
and a temperature gradient of 2◦C/min was applied from 20
to 95◦C. During the gradient, the fluorescence at 330 and
350 nm were measured to determine the melting temperature
TM. Data processing was performed using the Prometheus
ThermControl v.2.1.2.
Downstream Processing Test Procedure
ScFv-conjugated columns were analyzed on a Bio-Rad NGC
FPLC system. Each column was washed with sample buffer for
at least 10 CV prior testing. The testing protocol included the
following chromatography steps: (1) 5 CV sample buffer; (2) 5
CV elution buffer; (3) 5 CV sample buffer; (4) Sample application
[3 mg Gamunex (Bayer)]. Gamunex is a therapeutic product
for patients with an immunoglobulin deficiency. It contains a
mixture of 98%-pure IgG-isotypes with a ratio of IgG1 62.8%,
IgG2 29.7%, IgG3 4.8%, and IgG4 2.7%. (5) 10 CV sample buffer;
(6) 5 CV sample buffer/elution buffer (mixed in variable ratios);
(7) 5 CV elution buffer; (8) 5 CV sample buffer. Depending
on the performed test series, phosphate citrate pH 7.4 was
utilized as sample buffer (pH-test series) or Tris/HCl 50 mM
pH 7.0 (magnesium-test series), respectively. As elution buffer,
either phosphate citrate pH 3.0 or Tris/HCl 50 mM pH 7.0,
MgCl2 2 M was utilized. To evaluate the recovery at the utilized
pH/magnesium concentration, the area under curve for the first
elution step was divided by the total area under curve for both
peaks multiplied by 100, resulting in percent values. Unless
otherwise indicated, pH test series were performed at flowrates
of 3 mL/min (except sample application with 1 mL/min) whereas
magnesium test series were performed at 1 mL/min.
Expression of Trastuzumab
For the purification experiments, Trastuzumab was produced
according to published procedures (Schneider et al., 2019). The
purification was performed either with a Protein A HP 1 mL
column (GE Healthcare) or a self-produced column with 15 mL
cell culture supernatant (diluted 1:2 with phosphate citrate buffer
pH 7.4) with a two-step purification protocol described in the
downstream processing test procedure paragraph.
Biolayer Interferometry
The binding kinetics were determined utilizing the Octet
RED96 system (ForteBio, Pall Life Science). Measurements were
performed at 30◦C and 1000 rpm. All biosensors were incubated
in PBS prior to utilization for at least 10 min. After determination
of the baseline in PBS buffer for 30 s, the anti-human Fab-sensors
(FAB2G) were loaded with daratumumab at a concentration of
1 µg/ml in PBS for 300 s. Quenching of the biosensors was
performed for 60 s in kinetic buffer (ForteBio, Pall Life Science)
prior to incubation of the sensors with varying concentrations
(25–800 nM) of scFv in PBS for 600 s (H9; M9) or 720 s
(M2). The dissociation of the antigen was measured for 600 s
in phosphate-citrate-buffer at the respective pH (pH 5.0, pH 4.5,
or pH 4.0). For each BLI experiment, a negative control was
measured in which the biosensor was incubated in PBS instead
of the IgG1 antibody. This negative control was subtracted from
all antigen containing samples. Data analysis was performed with
ForteBio data analysis software 9.0 using a 1:1 binding model
with Savitzky–Golay filtering. For KD determination, at least
three different scFv concentrations were used for a global fit. For
the dissociation, only the fast dissociation step was considered
for calculation (H9: 45 s; M2: 30 s; M9: 30 s) as described by
Molecular Devices (Renee and Weilei, 2017). The Kdis values
in different buffers were measured at single concentrations (H9:
500 nM; M2: 400 nM; M9: 250 nM).
RESULTS
Our previous immunization campaigns of chickens indicated
that a high diversity of antibodies against mammalian antigens
can be obtained (Grzeschik et al., 2019). Hence, we reasoned
that this repertoire might contain several antibodies that display
per se pH- and/or magnesium responsive binding. To test this
hypothesis, we used a human SEED-Fc fragment as antigen
for chicken immunization. A SEED-Fc consists of an IgG CH2
domain and a strand-exchanged IgG CH3. The strand exchanges
were made with an CH3 of an IgA (Davies et al., 1995). A serum
sample withdrawn 35 days after immunization indicated a strong
immune response (data not shown). RNA was isolated from
spleen tissue and cDNA was prepared by reverse transcription.
The cDNA was amplified by PCR and VL und VH chains
were randomly combined into scFv fragments by SOE PCR
as described (Grzeschik et al., 2019). After transfer into yeast
display vector pCT by gap repair (Benatuil et al., 2010) a yeast
display library was generated in 1 day comprising approximately
5.2× 109 transformants.
To exclusively obtain Fc binding antibodies, four different
antigens [daratumumab (Janssen-Cilag), pertuzumab
(Genentech), cetuximab (Merck), Fc-fusion protein] all
sharing a common human IgG1-Fc fragment, were used
for screening. Starting with 1.6 × 108 clones of the initial
library which displayed a surface presentation level of 37.8%
(Supplementary Figure S1), obviating the need for a magnetic
bead preselection step, two consecutive FACS sorting rounds
were performed with 1 µM Fc-fusion in the first sorting round
and after cell growth with 1 µM of the human therapeutic
antibody daratuzumab in the second sorting round to enrich
Fc-binding scFv variants. To this end, yeast cells were sorted that
showed fluorescence indicative of target binding and also for
yeast surface presentation of the scFv resulting in 0.32% (round
1) and 35.4% (round 3) sorted yeast cells (Figure 1A). After
the second sorting round, strong enrichment of binders was
observed (Figure 1A). Afterward, the library was split into two
different batches. One batch was further utilized to isolate pH-
responsive scFvs whereas the second batch was utilized to screen
for Mg-responsive scFvs (from now on called pH-batch and
Mg-batch, respectively). In order to isolate pH-responsive scFvs,
the yeast cells from the pH-batch were stained with 250 nM
pertuzumab and FITC-labeled anti-Fab antibody. Afterward,
cells were incubated at pH 5.0 for 5 min and those yeast cells
were isolated that showed surface presentation but lacked target
binding (Figure 1D). Prior to single clone analysis, a 5th sorting
round was performed using 150 nM daratumumab to isolate
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single clones that showed target binding at pH 7.4 (Figure 1D).
All FACS plots showing the sorting for pH-responsive scFvs are
depicted in Supplementary Figure S2.
Magnesium-responsive scFvs were generated within three
consecutive FACS rounds after the initial library enrichment.
To this end, two consecutive selection rounds were performed
by screening for non-binders upon indirect cell staining with
1 µM cetuximab followed by subsequent incubation in Tris/HCl
buffer pH 7.0 with 2 M MgCl2. Sorted cells lacking the target
binding fluorescence signal under these conditions increased
from 1.8 to 3.3%, respectively (Figure 1B). The last sorting round
prior to single clone analysis was performed via screening for
binders of 150 nM daratumumab with no MgCl2 added to ensure
enrichment of Fc-specific binders after two rounds of sorting for
non-binding scFvs. The complete sorting campaign is shown in
Supplementary Figure S3.
Eight pH- and nine magnesium-responsive single clones
were picked and analyzed toward their binding properties in
either phosphate-citrate pH 5.0 buffer (Dawson et al., 1987)
or Tris/HCl 2 M MgCl2 buffer (pH 7.0), respectively. To this
end, 5 × 106 yeast cells of each putative pH-responsive single
clone were collected by centrifugation and stained with 100 nM
pertuzumab and APC labeled anti-kappa antibody for target
binding and a biotinylated anti-myc-epitope antibody followed
by streptavidin R-phycoerythrin (SPE) staining for surface
presentation (Supplementary Figure S4A). Except for single
clone H2, all variants showed pH-responsive behavior and were
therefore considered for reformatting and expression. In FACS
analysis, H7 and H9 exhibited significant loss of target binding
at pH 5.0 (exemplarily shown for H9 in Figure 1E). Putative
yeast-displayed magnesium responsive variants were tested
toward target binding via FACS with 150 nM daratumumab
(exemplarily shown for M9 in Figure 1E, data for all single clones
depicted in Supplementary Figure S4B). Single clone 1 and 7
showed no or only minor target binding decrease after MgCl2
treatment and were therefore excluded from further experiments.
Responsive variants were sequenced and reformatted into a
pET30 expression plasmid via golden gate cloning with a
N-terminal His6-tag and a C-terminal StrepTagII to be used as
purification handles. Seven unique pH-responsive variants were
expressed which could be allocated to four different sequence
clusters (H1–H9). Likewise, the magnesium-responsive variants
showed high diversity with five unique variants out of eight
belonging to four different clusters (M2-M9) (Table 1).
The melting temperature for every expressed protein was
determined by Nano differential scanning fluorimetry. The
measurements showed TM values in line with published melting
temperatures for chicken scFvs ranging from 48 and 68◦C
(Table 1) with H1, M3, M9 having melting temperatures
exceeding 60◦C, comparable to Fab molecules (Orr et al., 2003;
Garber and Demarest, 2007; Miller et al., 2010). For some
variants, two distinct melting temperatures could be observed.
This might be due to different melting temperatures for the VL
and the VH domain (Miller et al., 2010).
For the chromatography experiments, 5 mg of each scFv
were utilized for coupling to NHS-agarose columns. The
coupling efficiency varied between 67 and 96% (Table 1).
Prepared columns were stored at 4◦C until further utilization.
All chromatographic procedures were performed on a NGS
Bio-Rad system with pH-module calibration between each
column experiment set. A column experiment set includes a
pH-gradient (pH 3.0–7.4) and up to eight different isocratic
elution chromatographies for pH-experiments or a MgCl2-
gradient (0–2 M MgCl2) and up to five different isocratic elution
chromatographies, respectively.
To determine the recovery, a two-step isocratic elution was
performed. The first isocratic step was performed in phosphate-
citrate-buffer with variable pH (Figure 2A – Elution 1). The
second elution step was performed in phosphate-citrate-buffer
pH 3.1–3.3 ensuring the elution of remaining IgG on the column
(Figure 2A – Elution 2). The area under curve (AUC) was
determined for each elution step. The AUC ratio of the first
elution step and the sum of the first and second elution step
resulted in a percentage value which defines the recovery. In
comparison with Protein A, all proteins except H4 and H8
showed higher recovery, exceeding 90% at pH values >4.0. The
best variants, H7 and H9, displayed recovery of more than 92%
above pH 4.5 (Figure 2B).
The pH-experiments were also conducted with the
magnesium-responsive variants. Interestingly, three out of
five scFvs displayed pH-responsive behavior (Figure 2C).
Particularly M2, M6, and M3 revealed pH- responsive elution
behavior even outperforming Protein A at pH 4.0. M8 did not
show any elution at pH 3.2.
In the chromatography experiments with MgCl2 as eluant,
M8 was the best performing scFv showing quantitative elution
at 400 mM MgCl2, closely followed by M9. M2 performed
adequately with nearly quantitative elution at 800 mM MgCl2.
M3 and M6 only showed mediocre magnesium-responsiveness
with only 55 and 65% elution at 1000 mM MgCl2, respectively
(Figure 2D). As negative control, H7 and H9 were tested toward
their magnesium-responsiveness but did not show any protein
elution signal at 2 M MgCl2. To see whether the elution was
driven by high ionic strength or specifically by Mg2+ ions, bound
antibody on scFv M9 column was incubated with Tris/HCl buffer
pH 7.0 containing either 2 M NaCl, 2 M CaCl2 or 2 MgCl2,
respectively. It was apparent, that antibody elution was specific
for bivalent cations, with strong preference for Mg2+. In direct
comparison, Ca2+ only lead to a recovery of 80% with very strong
tailing, clearly demonstrating Mg2+ specificity (Figure 3).
An unexpected finding was the pH-dependent elution of M2,
M3, and M6. All three variants were examined in combinatorial
experiments with phosphate-citrate-buffer (pH 5.5–4.5) and low
concentrations of MgCl2 (0, 100, 200 mM). As expected, the
addition of MgCl2 significantly improved the recovery for all
tested variants (Figures 4A–C). As negative control, H7 was
also tested toward the combinatorial effects of MgCl2 and pH.
The addition of 100 mM MgCl2 was beneficial at pH 5.5 and
5.2 and slightly improved recovery. However, further increasing
the MgCl2 concentration did not further improve the elution
behavior (Figure 4D).
The most pH-responsive affinity ligands H7 and H9 were
utilized to investigate, whether the recovery can be further
enhanced by lowering the flow rate during elution from 3 ml/min
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TABLE 1 | Summary of TM values at pH 7.4 and pH 3.0 for all isolated pH- and magnesium-responsive scFvs including the observed yields and determined
coupling efficiencies.
Cluster TM1 pH 7.4 TM2 pH 7.4 TM1 pH 3.0 TM2 pH 3.0 Yield [mg/L] Coupling [%]
H1 III 60.5 68.4 40.55 50.00 4.7 n.d.
H3 II 45.7* – n.d. – 5.2 –
H4 I 55.4 – 27.8 – 12.7 96.5
H6 I 58.5 – 43.8 – 16.9 71.1
H7 I 57.95 70.35 43.85 56.5 4.8 n.d.
H8 II 52.3 – 49.0 – 24.4 71.3
H9 I 48.7 55.8 33.3 42.15 5.38 n.d.
M2 I 51.0 – 32.5 – 10.9 78.8
M3 II 61.2 – 38.1 – 8.1 67.2
M6 III 53.55 – 35.3 – 3.6 n.d.
M8 III 52.45 – n.d. – 5.14 75.1
M9 III 69.48 – 59.4 65.5 14.8 80.6
FIGURE 2 | Example chromatogram and recovery diagrams. (A) Sample chromatogram with the absorbance at 280 nm depicted on the y-axis (blue line) and the
elution volume on the x-axis. Additionally, the recorded pH is shown on the right y-axis in orange. Elution 1 and elution 2, which are used for determining the
recovery, are indicated by dashed lines on the x-axis. (B,D) Recovery for pH-responsive scFvs (B) and magnesium-responsive scFvs. The recovery is depicted on
the y-axis, the pH value on the x-axis. Each dot represents a single measurement (triangles for magnesium-responsive variants), scFvs are separated by color,
Protein A data points are depicted as stars. Vertical dashed lines indicate pH 4.0, pH 4.5 and pH 5.0, respectively, horizontal dashed lines indicate 90% recovery.
(C) Depiction of the recovery of Magnesium-responsive chicken scFvs. Dashed vertical lines indicate 250 mM, 500 mM, or 1000 mM MgCl2 concentration.
to 1 ml/min. It could be shown, that decreasing flow rate
gains 3–5% recovery (Supplementary Figure S5). In order to
evaluate the specificity of H9, an Expi293F culture was transiently
transfected with expression plasmids coding for trastuzumab
heavy chain and trastuzumab light chain, respectively. After
5 days of expression, the supernatant was filtered, diluted 1:2
with phosphate citrate buffer pH 7.4 and directly applied onto the
column. The elution was performed with phosphate citrate buffer
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FIGURE 3 | Selectivity test of M9 toward CaCl2, NaCl and MgCl2. Depiction
of the elution of 2 mg Gamunex bound to immobilized M9 by 2 M NaCl (blue),
2 M CaCl2 (green) or 2 M MgCl2 (red), respectively. Recovery as determined
by the AUC was 98.8% for MgCl2, 79.3% for CaCl2 and 8.2% for NaCl,
respectively.
at pH 4.6 in the first elution step. As revealed by SDS-PAGE,
it was possible to isolate trastuzumab from mammalian cell
culture supernatant at high yield and purity with a total recovery
of 98.7% (Figure 5). A likewise performed purification with a
Protein A HP 1 ml column showed no elution at pH 4.6 and the
antibody eluted at pH 3.0 off the column (Supplementary Figure
S9). Both purification procedures showed comparable elution
profiles, resulting in antibody recovery either at pH 4.6 (H9
functionalized column) or pH 3.0 (Protein A HP 1 ml column).
For the in depth characterization of the soluble affinity
ligands via Biolayer Interferometry (BLI), H9, M2 and M9
were chosen to be the most interesting molecules due to
their pH-responsive behavior (H9), their magnesium-responsive
binding in combination with high TM (M9), or their combined
magnesium and pH-responsive binding (M2). To this end,
Daratumumab was immobilized onto anti-Human Fab-CH1
biosensors. The sensors were quenched in kinetics buffer and
the association of the respective scFv was measured at different
concentrations (Supplementary Figure S6). The dissociation was
examined at pH 7.4, pH 5.0, and pH 4.5 respectively, as well
as at pH 7.0 with 200, 400, and 600 mM MgCl2 added. H9
displayed high affinity binding with a KD of 35.8 nM (Table 2).
The dissociation rate increased with lower pH. A 21-, 44-, 161-
fold enhanced dissociation was observed when placing the loaded
tips in phosphate-citrate-buffer at pH 5.0, pH 4.5, and pH 4.0,
respectively. Under similar conditions, M2 showed a 2.8, 5.4-, and
FIGURE 4 | Combinatorial experiments with varying magnesium concentration and varying pH values. pH is depicted on the x-axis, recovery on the y-axis. Blue
data points were ascertained in phosphate buffer (0 M MgCl2), red data points in phosphate buffer with 100 mM MgCl2 and green data points in phosphate buffer
with 200 mM MgCl2.
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FIGURE 5 | Trastuzumab purification from trastuzumab producing Expi293F cell culture supernatant. (A) Chromatogram of the purification of trastuzumab from
15 mL Expi293 supernatant. Absorbance at 280 nm is depicted on the left y-axis (blue), pH is shown on the right y-axis (violet). The elution volume is depicted on
the x-axis. Elution was performed in two steps with pH 4.6 and pH 3.0, respectively. (B) SDS-PAGE gel with the supernatant on the left lane and the purified sample
on the right lane, the protein ladder (Blue Prestained Protein Standard, Broad Range; New England Biolabs) is depicted on the middle lane.
TABLE 2 | Kinetic data gathered via BLI for M2, M9, and H9.
KD [nM] KD Error [nM] kon [M−1s−1] kon Error [M−1s−1] kdis [s−1] kdis Error [s−1]
M2 504 ±20.9 6.93 × 104 ±2.52 × 103 3.50 × 10−2 ±6.89 × 10−4
M9 290 ±16.1 6.01 × 104 ±2.89 × 103 1.74 × 10−2 ±4.83 × 10−4
H9 35.9 ±0.55 6.41 × 104 ±2.53 × 102 2.30 × 10−3 ±3.39 × 10−5
Data was obtained on an Octet RED96 system (ForteBio, Pall Life Science) with FAB2G sensors. Fitting was performed with ForteBio Data Analysis 9.0.0.14.
13-fold enhanced dissociation following the observations from
the previous on-column experiments, where H9 was significantly
more pH-responsive than M2. M2 and M9 exhibit medium
affinity with KD values in the triple digit nanomolar range of
504 and 290 nM, respectively. Interestingly, M2 and M9 did
only display a slightly increased dissociation with increasing
magnesium chloride concentrations (Table 3). We also checked
for cross-reactivity of M2, M9, and H9 toward IgG4 antibodies.
M2 and M9 did not show any binding signal toward IgG4,
whereas H9 did bind IgG4 with comparable affinity as IgG1
(data not shown). Further cross-reactivity checks have not been
performed since IgG1 and IgG4 are the most relevant isotypes in
a therapeutic context (Irani et al., 2015).
DISCUSSION
In this work, we describe the fast and straightforward generation
of chicken derived antibody fragments (scFvs) which can be used
as ligands in affinity chromatography. By using yeast surface
display and FACS it was possible to isolate chicken scFvs with
pH-responsive and magnesium-responsive dissociation profiles
which kept their responsive behavior upon immobilization on
solid phase. Generation of scFv libraries in yeast S. cerevisiae is a
well-established procedure (Feldhaus et al., 2003; Grzeschik et al.,
2019) that routinely allows one to generate more than 109 clones
in a single working day. In this experiments, 5.2 × 109 yeast
transformants were obtained from harvested chicken B-cells,
where more than 90% of the obtained clones contained a full
length scFv encoding gene.
The screening for pH-responsive scFvs was performed
according to previously reported screening campaigns for the
isolation of pH-responsive antibody fragments (Könning et al.,
2016; Bogen et al., 2019). In total, four sorting rounds were
necessary to isolate scFvs with desired properties including
only one negative sorting step to omit non-responsive binders.
Likewise, the isolation of magnesium-responsive scFvs was
performed within five sorting rounds including two consecutive
negative selection rounds (Figure 1).
A small subset of only 10 single clones of each campaign was
further analyzed, of which most displayed pH or magnesium-
responsive binding, or both which indicates that this FACS-based
shuttle-screening is a simple and robust procedure to enrich
antibodies with prescribed binding characteristics.
Sequence analysis revealed seven unique pH-responsive and
five unique magnesium-responsive scFv variants which could
be allocated to three clusters each. No cluster was shared
between both families, despite the fact that some of the
magnesium-responsive binders also displayed pH-dependent
binding. pH-dependent binding is often associated with a higher
occurrence of histidine residues in the antibody complementarity
determining regions since histidine is the only amino acid
that is uncharged at neutral pH and becomes positively
charged at acidic pH. The positive charge at lower pH
can induce repulsive electrostatic interactions in cases where
positive charges of the bound antigen are in close proximity
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to the antibody binding site (Murtaugh et al., 2011). We
have not observed unusual strong enrichment of histidines
in our described clones (data not shown). In addition, the
pH-responsive behavior can also be caused by destabilizing
the VH/VL interaction as well as the CDR loop arrangement
weakening the antigen-binding. Specific framework changes
to exploit ionisable groups in order to generate pH/calcium-
responsive proteins are described in literature (Gulich et al.,
2000; Kellmann et al., 2017; Kanje et al., 2018). Since we
have no detailed knowledge of the exact binding epitopes it
is currently unclear, which amino acids in the CDRs and the
bound target protein epitope and which type of interaction
account for the observed pH responsive binding. Aspartate and
glutamate are typically involved in magnesium complexation,
which could interfere with antigen binding (Dudev and Lim,
2007; Brylinski and Skolnick, 2011; Khrustalev et al., 2016).
Since these residues are also amenable to protonation at
acidic pH, and the microenvironment of the antigen-antibody
complex may occasionally promote a shift to higher pK of
these residues, it is tempting to speculate that these effects
account for the observed pH-responsive binding of several
obtained clones, that have exclusively been screened for reduced
binding at elevated magnesium concentration. Notably, the pH-
and magnesium-dependent binding is not due to denaturation
of the scFv at acidic pH or high magnesium concentrations
since melting temperatures were largely unchanged under
these conditions (Table 1). Furthermore, it was possible
to verify that the addition of MgCl2 can stabilize the
scFv and therefore elevate the observed melting temperature
(Supplementary Figure S7).
All scFvs could be expressed in E. coli SHuffle T7 Express cells
with low to medium expression levels. No efforts were made yet to
optimize expression yields, e.g., by codon optimization or using
culture media for high density growth. No efforts were made to
optimize the scFv loading density and target antibody binding
capacity. Coupling onto NHS-agarose columns was performed
with 5 mg protein resulting in coupling efficiencies of 67-96%. If
a 1:1 interaction is assumed, the column with the least amount
of coupled scFv (M3, 67%) should be capable of capturing
18.6 mg antibody which was considered sufficient to evaluate the
capturing performance.
Protein A is the gold standard for antibody purification
using mild elution conditions requiring a pH less than 4.0 for
release of bound antibody. H1, H6, H7, and H9 did show
efficient elution up to pH 4.0 with over 95% recovery which
exceeds the recovery of Protein A at pH 4.0. H7 and H9 – both
originated from the same cluster – appeared to be the most
pH-responsive variants with close to quantitative elution at pH
4.5 (Figure 2B). The magnesium-responsive variants M2, M3,
and M6 also showed more efficient elution than Protein A at
pH 4.0. However, the most magnesium-responsive variants M8
and M9 did not show pH-responsive Fc binding. We found that
combining pH-changes dependent on Mg2+-concentration can
significantly increase recovery. Particularly for M2 we found that
low MgCl2 concentrations will increase the recovery from 40%
to 90% at ∼pH 5.0 (Figure 4). Also, the flow rate decrease from
3 ml/min to 1 ml/min lead to an increase of approx. 5% at pH
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4.6 for H9 (Supplementary Figure S5) indicating that elution
conditions might be further tuneable if desired.
In recent years, the Capture SelectTM strategy was introduced
that relies on the isolation of camelid VHH domain that
selectively bind various type of antibodies. These have also
been developed for antibody affinity purification and elution
at acidic pH or using elevated magnesium concentrations
(Hermans et al., 2017). Little information is available in literature
about the screening procedure, but multiple formats against
different antibody formats have been developed upon lama
immunization and subsequent phage display screening (Klooster
et al., 2007; Detmers et al., 2010; Reinhart et al., 2012).
Notably, in comparison to camelid derived VHHs that require
a magnesium burst of 1 M MgCl2 in combination with 40%
propylene glycol for elution, chicken scFvs isolated in this work
showed elution at neutral pH with significantly reduced MgCl2
concentration (400 mM).
The observed KD values for H9, M2 and M9 ranged from
40 nM to over 500 nM, well in the range of affinities sufficient
for affinity chromatography as described by literature (Anspach,
2004; Mondal et al., 2006; Chen et al., 2014). Watanabe et al.
(2009) engineered pH-responsive Protein G variants by rational
design comprising similar KD values. Their best variant showed
an affinity decrease of 80-fold at 4.0 which is clearly exceeded
by H9 with an affinity decrease of 161-fold. The findings for the
magnesium-buffer dependency of target release were surprisingly
not correlating to the on-column experiments. M9 displayed
better recovery but less affinity decrease in the BLI experiments
compared to M2. This indicates that the artificial conditions in
the BLI setup do not correlate very well to the binding conditions
of the scFv and the antigen on column.
Lastly, usability of chicken scFvs for affinity chromatography
was underlined by the fact that no decrease in column
capacity was observed during the testing period over up to 18
chromatography cycles. Additionally, no decrease in AUC was
observed in a repeated cycle experiment were five consecutive
chromatography runs were performed with H7 (Supplementary
Figure S8) after all test runs.
In summary, in this work, we describe as straightforward
procedure for the isolation of chicken antibody-based affinity
ligands for affinity chromatography. We demonstrated that the
immunization of chicken and the subsequent FACS selection
process delivers a plethora of different ligands which can be
individually optimized for chromatography applications. It is
important to note that this generic strategy can also be applied
to the purification of proteins with therapeutic relevance other
than monoclonal antibodies.
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